Essex Bio-Technology Limited disclosed a share repurchase executed on 6 August 2026, acquiring 191,000 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 2.36 and HKD 2.38 per share. The volume-weighted average purchase price was approximately HKD 2.3705, bringing total cash outlay to HKD 0.45 million.

Post-transaction, Essex Bio-Tech’s outstanding share count (excluding treasury shares) decreased by 0.03% to 565.46 million. Treasury stock rose from 1.36 million to 1.55 million shares, while the company’s total issued share capital remained unchanged at 567.01 million shares.

The repurchase forms part of the mandate granted by shareholders on 26 May 2026, which authorises the company to buy back up to 56.70 million shares. Cumulative purchases under this mandate now stand at 1.55 million shares, equivalent to 0.27% of the company’s issued share capital at the mandate date.

In line with Hong Kong Listing Rule 10.06(3)(a), Essex Bio-Tech is restricted from issuing new shares or disposing of treasury shares until 5 September 2026.